Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $69 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 331.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is more actively traded (10,680,748 versus 2,742,564). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 132 Days on average.
| MRVI | VEA | |
|---|---|---|
Market Cap | $977.37M | $323.80B |
Volume | 2,742,564 | 10,680,748 |
Sector | Health | — |
52-Week High | $9.00 | $73.79 |
52-Week Low | $2.83 | $58.90 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
VEA trades at $70.06, up 0.16% today, with a bearish technical signal driven by moving averages. The ETF offers exposure to developed markets outside the U.S. with a low 0.03% expense ratio and a dividend yield. Recent institutional activity is mixed, with some firms increasing stakes while others reduced positions.
The outlook is neutral to cautious given bearish technicals and mixed sentiment. Key opportunities include cost efficiency and diversification benefits, but risks involve global market volatility and currency fluctuations. Investors should weigh the ETF's low-cost structure against broader economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
